antiinflammatory/antirheumatic agents in combination	is a	medication
antiinflammatory/antirheumatic agents in combination	treats	rheumatoid arthritis
antiinflammatory/antirheumatic agents in combination	treats	osteoarthritis
antiinflammatory/antirheumatic agents in combination	reduces	inflammation
antiinflammatory/antirheumatic agents in combination	alleviates	pain
antiinflammatory/antirheumatic agents in combination	may include	NSAIDs
antiinflammatory/antirheumatic agents in combination	may include	DMARDs
antiinflammatory/antirheumatic agents in combination	may include	corticosteroids
antiinflammatory/antirheumatic agents in combination	can cause	gastrointestinal bleeding
antiinflammatory/antirheumatic agents in combination	can cause	liver damage
antiinflammatory/antirheumatic agents in combination	requires	monitoring
antiinflammatory/antirheumatic agents in combination	interacts with	anticoagulants
antiinflammatory/antirheumatic agents in combination	contraindicated in	peptic ulcer disease
antiinflammatory/antirheumatic agents in combination	metabolized in	liver
antiinflammatory/antirheumatic agents in combination	excreted by	kidneys
antiinflammatory/antirheumatic agents in combination	prescribed for	autoimmune diseases
antiinflammatory/antirheumatic agents in combination	improves	joint mobility
antiinflammatory/antirheumatic agents in combination	slows	disease progression
antiinflammatory/antirheumatic agents in combination	may require	dose adjustment
antiinflammatory/antirheumatic agents in combination	affects	immune system
NSAIDs	inhibit	COX enzymes
DMARDs	modify	immune response
corticosteroids	suppress	inflammation
gastrointestinal bleeding	caused by	NSAIDs
liver damage	monitored through	liver function tests
monitoring	involves	blood tests
anticoagulants	increased risk of	bleeding
peptic ulcer disease	aggravated by	NSAIDs
liver	processes	drug metabolism
kidneys	filter	drug metabolites
autoimmune diseases	characterized by	chronic inflammation
joint mobility	improved by	pain reduction
disease progression	measured by	imaging studies
dose adjustment	based on	renal function
immune system	modulated by	DMARDs
COX enzymes	produce	prostaglandins
immune response	regulated by	cytokines
inflammation	mediated by	inflammatory markers
liver function tests	assess	hepatotoxicity
blood tests	detect	side effects
bleeding	prevented by	proton pump inhibitors
NSAIDs	combined with	gastroprotective agents
drug metabolites	eliminated via	urine
chronic inflammation	leads to	tissue damage
pain reduction	improves	quality of life
imaging studies	show	joint erosion
renal function	determines	drug clearance
cytokines	targeted by	biologic agents
prostaglandins	cause	pain
inflammatory markers	include	CRP
hepatotoxicity	indicated by	elevated enzymes
side effects	managed by	dose reduction
proton pump inhibitors	protect	gastric mucosa
gastroprotective agents	prevent	ulcers
urine	contains	drug byproducts
tissue damage	results in	disability
quality of life	assessed by	questionnaires
joint erosion	seen on	X-rays
drug clearance	affected by	age
biologic agents	block	TNF-alpha
CRP	measures	inflammation severity
elevated enzymes	suggest	liver injury
dose reduction	minimizes	toxicity
gastric mucosa	damaged by	NSAIDs
ulcers	treated with	antacids
drug byproducts	detected in	lab tests
disability	measured by	HAQ score
questionnaires	evaluate	patient symptoms
X-rays	reveal	joint space narrowing
age	influences	drug sensitivity
TNF-alpha	promotes	inflammation
inflammation severity	correlates with	ESR
liver injury	treated with	medication cessation
toxicity	prevented by	therapeutic drug monitoring
antacids	neutralize	stomach acid
lab tests	monitor	drug levels
HAQ score	assesses	functional status
patient symptoms	include	morning stiffness
joint space narrowing	indicates	osteoarthritis
drug sensitivity	varies by	genetics
ESR	reflects	inflammatory activity
medication cessation	reverses	adverse effects
therapeutic drug monitoring	optimizes	treatment
stomach acid	irritates	esophagus
drug levels	guide	dosing
functional status	impacts	daily activities
morning stiffness	lasts	hours
osteoarthritis	involves	cartilage breakdown
genetics	affect	drug metabolism
inflammatory activity	predicts	disease flares
adverse effects	reported to	FDA
treatment	tailored to	individual needs
esophagus	protected by	sucralfate
dosing	adjusted for	body weight
daily activities	limited by	joint pain
cartilage breakdown	leads to	bone spurs
drug metabolism	influenced by	liver enzymes
disease flares	managed with	steroid pulses
FDA	regulates	drug safety
individual needs	determined by	comorbidities
